A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers

Inclusion Criteria: * Healthy male and female non-smoking subjects, 18 to 55 years of age * Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination * Medical history without major, recent or ongoing pathology * Weight \>/= 50.0 kg * Body mass index (BMI) 18.0 - 32.0 kg/m2 Exclusion Criteria: * Pregnant or lactating women or males with female partners who are pregnant or lactating * History of any clinically significant medical condition which may impact the safety of the participant * Positive results for drugs of abuse at screening or prior to admission to the clinical site during any study period * Positive for hepatitis B, hepatitis C or HIV infection * Current smokers or subjects who have discontinued smoking less than 6 months prior to first dose of study medication * Use of hormonal contraceptives (e.g. birth control pill, patches, or injectable, implantable devices) within 30 days before the first dose of study medication * Use of investigational drug or device within 30 days of the first dose of study medication (6 months for biologic therapies) or 5 half-lives of the investigational drug, whichever is longer * History of drug-related allergic reaction * History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average; alcohol consumption will be prohibited 72 hours prior to entry in the clinical site center and throughout the entire study